Evidence map›Paper›PMID 31933881›Full record

ArticleInternational journal of clinical and experimental pathology2019

A detrimental mutation on USP40 unlocks the tumorigenesis in a rare case of lung cancer.

Zhi-Hong Xu, Hui Wang, Xiao-Yang Ji, Fei-Xu Zhang, Bei-Li Gao, Jia-An Hu, Jing Zheng

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 82% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Zhi-Hong XuDepartment of Geriatrics, Ruijin Hospital, Shanghai Jiaotong University Shanghai, P. R. China.
Hui WangLaboratory of Molecular Neuropharmacology, School of Pharmacy East China University of Science and Technology Shanghai, P. R. China.
Xiao-Yang JiDepartment of Geriatrics, Ruijin Hospital, Shanghai Jiaotong University Shanghai, P. R. China.
Fei-Xu ZhangLaboratory of Molecular Neuropharmacology, School of Pharmacy East China University of Science and Technology Shanghai, P. R. China.
Bei-Li GaoDepartment of Respiratory Medicine, Ruijin Hospital, Shanghai Jiaotong University Shanghai, P. R. China.
Jia-An HuDepartment of Geriatrics, Ruijin Hospital, Shanghai Jiaotong University Shanghai, P. R. China.
Jing ZhengLaboratory of Molecular Neuropharmacology, School of Pharmacy East China University of Science and Technology Shanghai, P. R. China.
Ruijin Hospital · CNEast China University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) is the most common histologic subtype of lung cancer. Previous research has shown heterogeneity in lung cancer, with the parallel existence of multiple subclones characterized by their own specific mutational landscape. The aim of our study was to gain insight into the evolutionary pattern of lung cancer by investigating the genomic heterogeneity between a nodule and its distant tumor. Luckily, we obtained nodule and tumor samples derived from surgery and a blood sample from a single patient. The samples are very unique, for tissues with the same genetic background from nodules to malignant tumors are rarely available and require precise micro-cutting. In this study, we performed whole-genome sequencing of these two samples, to identify novel candidate driver genes associated with LUAD. The nodule and tumor were found to have common significant ubiquitin-specific protease 40 (USP40) mutations, indicating an important driver role for the gene. Moreover, we also observed the two novel candidate driver genes ASCL5 and CAPNS1 in the LUAD sample. In summary, we pinpoint the predominant mutations in LUAD by WES, highlighting the substantial genetic alterations contributing to LUAD tumorigenesis. This may provide a better understanding of the clonal evolution during tumor development.

Indexed as

Lung adenocarcinoma tumorigenesissubclonal mutationsUSP40

Identifiers

PMID31933881
PMCPMC6945189
OpenAlexW3027673785

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.